Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 1
2013 4
2014 5
2015 5
2016 3
2017 2
2018 6
2019 4
2020 6
2021 3
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A. Emmett L, et al. Among authors: eu p. Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36872949 Free PMC article.
Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Ho B, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Hickey A, Eu P, Stockler M, Martin AJ, Joshua AM, Nguyen A, Emmett L. Pathmanandavel S, et al. Among authors: eu p. J Nucl Med. 2023 Feb;64(2):221-226. doi: 10.2967/jnumed.122.264398. Epub 2022 Aug 25. J Nucl Med. 2023. PMID: 36008120 Free PMC article.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. Pathmanandavel S, et al. Among authors: eu p. J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738906 Free PMC article. Clinical Trial.
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial.
Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, Gedye C, Kwan EM, Hauser C, Azad AA, Eu P, Martin AJ, Joshua AM, Emmett L. Pathmanandavel S, et al. Among authors: eu p. J Nucl Med. 2022 Apr;63(4):560-566. doi: 10.2967/jnumed.121.262552. Epub 2021 Jul 29. J Nucl Med. 2022. PMID: 34326127 Free PMC article. Clinical Trial.
Single-arm prospective interventional study assessing feasibility of using gallium-68 ventilation and perfusion PET/CT to avoid functional lung in patients with stage III non-small cell lung cancer.
Bucknell N, Hardcastle N, Jackson P, Hofman M, Callahan J, Eu P, Iravani A, Lawrence R, Martin O, Bressel M, Woon B, Blyth B, MacManus M, Byrne K, Steinfort D, Kron T, Hanna G, Ball D, Siva S. Bucknell N, et al. Among authors: eu p. BMJ Open. 2020 Dec 10;10(12):e042465. doi: 10.1136/bmjopen-2020-042465. BMJ Open. 2020. PMID: 33303468 Free PMC article. Clinical Trial.
Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.
Rajapaksa AE, Do LAH, Suryawijaya Ong D, Sourial M, Veysey D, Beare R, Hughes W, Yang W, Bischof RJ, McDonnell A, Eu P, Yeo LY, Licciardi PV, Mulholland EK. Rajapaksa AE, et al. Among authors: eu p. Front Pharmacol. 2020 Aug 19;11:1291. doi: 10.3389/fphar.2020.01291. eCollection 2020. Front Pharmacol. 2020. PMID: 32973520 Free PMC article.
Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN).
Crumbaker M, Pathmanandavel S, Yam AO, Nguyen A, Ho B, Chan L, Ende JA, Rofe C, Kongrak K, Kwan EM, Azad AA, Sharma S, Pugh TJ, Danesh A, Keane J, Eu P, Joshua AM, Emmett L. Crumbaker M, et al. Among authors: eu p. Eur Urol Oncol. 2021 Dec;4(6):963-970. doi: 10.1016/j.euo.2020.07.002. Epub 2020 Aug 3. Eur Urol Oncol. 2021. PMID: 32758400 Clinical Trial.
35 results